Comparative Pharmacology
Head-to-head clinical analysis: ASACOL versus BALSALAZIDE DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL versus BALSALAZIDE DISODIUM.
ASACOL vs BALSALAZIDE DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asacol (mesalamine) is an aminosalicylate that exerts anti-inflammatory effects in the colon via inhibition of prostaglandin and leukotriene synthesis, particularly by blocking cyclooxygenase and lipoxygenase pathways, and by scavenging reactive oxygen species. It also inhibits cytokine production and reduces mucosal inflammation.
Prodrug that delivers mesalamine (5-aminosalicylic acid) to the colon; mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, and scavenges reactive oxygen species, thereby decreasing colonic inflammation.
800 mg orally three times daily or 1600 mg three times daily for 6 weeks; maintenance: 1.6 g daily in divided doses.
2.25 g (three 750 mg capsules) orally three times daily
None Documented
None Documented
Terminal half-life: 0.6-1.4 hours for 5-ASA; 6-12 hours for N-acetyl-5-ASA. Clinical context: short t1/2 necessitates multiple daily dosing for sustained colonic exposure.
Balsalazide itself has a terminal elimination half-life of approximately 0.5–1 hour; the active moiety mesalamine has a terminal half-life of 5–10 hours, which may be prolonged in renal impairment.
Renal (80% as 5-ASA and N-acetyl-5-ASA), fecal (20%)
Primarily excreted in feces via biliary elimination (approximately 90%) following conversion to mesalamine; renal excretion accounts for less than 10% of the dose as mesalamine and its metabolites.
Category C
Category C
Aminosalicylate
Aminosalicylate